keyword
https://read.qxmd.com/read/37668515/the-unexpected-benefit-of-tcr-cross-reactivity-in-cancer-immunotherapy
#21
JOURNAL ARTICLE
Florian Bieberich, Sai Reddy
The ability of T cell receptors (TCR) to recognize tumor associated antigens (TAAs) is a key driver of adoptive transfer of tumor infiltrating lymphocyte T cells (TIL), which can be a highly effective cancer immunotherapy. While it is common knowledge that TCRs are cross-reactive and can bind multiple different peptide antigens, this is typically considered an unattractive feature and limitation for TCR-based therapies. In a recent publication in Cell, Dolton and colleagues discover that certain TCRs, isolated from TILs used for successful treatment of melanoma, possesses beneficial cross-reactivity by recognizing multiple TAA (1)...
September 5, 2023: Cancer Research
https://read.qxmd.com/read/37629075/targeting-melanoma-associated-fibroblasts-mafs-with-activated-%C3%AE-%C3%AE-v%C3%AE-2-t-cells-an-in-vitro-cytotoxicity-model
#22
JOURNAL ARTICLE
Anna Hajdara, Uğur Çakır, Barbara Érsek, Pálma Silló, Balázs Széky, Gábor Barna, Shaaban Faqi, Miklós Gyöngy, Sarolta Kárpáti, Krisztián Németh, Balázs Mayer
The tumor microenvironment (TME) has gained considerable scientific attention by playing a role in immunosuppression and tumorigenesis. Besides tumor cells, TME is composed of various other cell types, including cancer-associated fibroblasts (CAFs or MAFs when referring to melanoma-derived CAFs) and tumor-infiltrating lymphocytes (TILs), a subpopulation of which is labeled as γδ T cells. Since the current anti-cancer therapies using γδ T cells in various cancers have exhibited mixed treatment responses, to better understand the γδ T cell biology in melanoma, our research group aimed to investigate whether activated γδ T cells are capable of killing MAFs...
August 17, 2023: International Journal of Molecular Sciences
https://read.qxmd.com/read/37507543/alterations-in-immune-cell-phenotype-and-cytotoxic-capacity-in-her2-breast-cancer-patients-receiving-her2-targeted-neo-adjuvant-therapy
#23
RANDOMIZED CONTROLLED TRIAL
Nicola Gaynor, Alfonso Blanco, Stephen F Madden, Barry Moran, Jean M Fletcher, Damien Kaukonen, Javier Sánchez Ramírez, Alex J Eustace, Martina S J McDermott, Alexandra Canonici, Sinead Toomey, Ausra Teiserskiene, Bryan T Hennessy, Norma O'Donovan, John Crown, Denis M Collins
BACKGROUND: The phase II neo-adjuvant clinical trial ICORG10-05 (NCT01485926) compared chemotherapy in combination with trastuzumab, lapatinib or both in patients with HER2+ breast cancer. We studied circulating immune cells looking for alterations in phenotype, genotype and cytotoxic capacity (direct and antibody-dependent cell-mediated cytotoxicity (ADCC)) in the context of treatment response. METHODS: Peripheral blood mononuclear cells (PBMCs) were isolated from pre- (n = 41) and post- (n = 25) neo-adjuvant treatment blood samples...
October 2023: British Journal of Cancer
https://read.qxmd.com/read/37441083/serum-derived-extracellular-vesicles-from-breast-cancer-patients-contribute-to-differential-regulation-of-t-cell-mediated-immune-escape-mechanisms-in-breast-cancer-subtypes
#24
JOURNAL ARTICLE
Rosalind Graham, Patrycja Gazinska, Birong Zhang, Atousa Khiabany, Shubhankar Sinha, Thanussuyah Alaguthurai, Fabian Flores-Borja, Jose Vicencio, Fabienne Beuron, Ioannis Roxanis, Rafal Matkowski, Revadee Liam-Or, Andrew Tutt, Tony Ng, Khuloud T Al-Jamal, You Zhou, Sheeba Irshad
BACKGROUND: Intracellular communication within the tumour is complex and extracellular vesicles (EVs) have been identified as major contributing factors for the cell-to-cell communication in the local and distant tumour environments. Here, we examine the differential effects of breast cancer (BC) subtype-specific patient serum and cell-line derived EVs in the regulation of T cell mediated immune responses. METHODS: Ultracentrifugation was used to isolate EVs from sera of 63 BC patients, 15 healthy volunteers and 4 human breast cancer cell lines...
2023: Frontiers in Immunology
https://read.qxmd.com/read/37417941/a-prognostic-model-based-on-residual-cancer-burden-and-tumor-infiltrating-lymphocytes-on-residual-disease-after-neoadjuvant-therapy-in-her2-breast-cancer
#25
JOURNAL ARTICLE
Federica Miglietta, Moira Ragazzi, Bethania Fernandes, Gaia Griguolo, Davide Massa, Fabio Girardi, Michele Bottosso, Alessandra Bisagni, Giovanni Zarrilli, Francesca Porra, Daniela Iannaccone, Leocadia Dore, Mariangela Gaudio, Giacomo Santandrea, Matteo Fassan, Marcello Lo Mele, Rita De Sanctis, Alberto Zambelli, Giancarlo Bisagni, Valentina Guarneri, Maria Vittoria Dieci
PURPOSE: We aim to evaluate the prognostic significance of tumor-infiltrating lymphocyte on residual disease (RD-TIL) in HER2+ breast cancer (BC) patients who failed to achieve pathologic-complete response (pCR) after anti-HER2+chemotherapy (CT)-based neoadjuvant treatment (NAT). We assessed the feasibility of combining the prognostic information provided by residual cancer burden (RCB) and RD-TILs into a composite score (RCB+TILs). EXPERIMENTAL DESIGN: HER2+ BC patients treated with CT+anti-HER2-based NAT at three institutions were retrospectively included...
July 7, 2023: Clinical Cancer Research
https://read.qxmd.com/read/37384291/heterogenous-profiles-between-primary-lung-cancers-and-paired-brain-metastases-reveal-tumor-evolution
#26
JOURNAL ARTICLE
Yanming Chen, Xiaoxiao Dai, Ji Wang, Chuming Tao, Ye Wang, Qing Zhu, Zhongyong Wang, Tan Zhang, Qing Lan, Jizong Zhao
BACKGROUND: Brain metastases (BMs) are the most common central nervous system (CNS) malignant tumors, with rapid disease progression and extremely poor prognosis. The heterogeneity between primary lung cancers and BMs leads to the divergent efficacy of the adjuvant therapy response to primary tumors and BMs. However, the extent of heterogeneity between primary lung cancers and BMs, and the evolutionary process remains little known. METHODS: To deeply insight into the extent of inter-tumor heterogeneity at a single-patient level and the process of these evolutions, we retrospectively analyzed a total of 26 tumor samples from 10 patients with matched primary lung cancers and BMs...
2023: Frontiers in Oncology
https://read.qxmd.com/read/37377887/reprogramming-of-tumor-reactive-tumor-infiltrating-lymphocytes-to-human-induced-pluripotent-stem-cells
#27
JOURNAL ARTICLE
S M Rafiqul Islam, Takuya Maeda, Naritaka Tamaoki, Meghan L Good, Rigel J Kishton, Biman C Paria, Zhiya Yu, Marta Bosch-Marce, Nicole M Bedanova, Chengyu Liu, Michael J Kruhlak, Nicholas P Restifo, Raul Vizcardo
UNLABELLED: Tumor-infiltrating lymphocytes (TIL) that can recognize and kill tumor cells have curative potential in subsets of patients treated with adoptive cell transfer (ACT). However, lack of TIL therapeutic efficacy in many patients may be due in large part to a paucity of tumor-reactive T cells in TIL and the exhausted and terminally differentiated status of those tumor-reactive T cells. We sought to reprogram exhausted TIL that possess T-cell receptors (TCR) specific for tumor antigens into induced pluripotent stem cells (iPSC) to rejuvenate them for more potent ACT...
May 2023: Cancer Res Commun
https://read.qxmd.com/read/37339797/method-for-estimation-of-apoptotic-cell-fraction-of-cytotherapy-using-in-vivo-fluorine-19-magnetic-resonance-pilot-study-in-a-patient-with-head-and-neck-carcinoma-receiving-tumor-infiltrating-lymphocytes-labeled-with-perfluorocarbon-nanoemulsion
#28
JOURNAL ARTICLE
Eric T Ahrens, Brooke M Helfer, Charles F O'Hanlon, Deanne R Lister, Julie L Bykowski, Karen Messer, Benjamin I Leach, Jiawen Chen, Hongyan Xu, Gregory A Daniels, Ezra E W Cohen
BACKGROUND: Adoptive transfer of T cells is a burgeoning cancer therapeutic approach. However, the fate of the cells, once transferred, is most often unknown. We describe the first clinical experience with a non-invasive biomarker to assay the apoptotic cell fraction (ACF) after cell therapy infusion, tested in the setting of head and neck squamous cell carcinoma (HNSCC). A patient with HNSCC received autologous tumor-infiltrating lymphocytes (TILs) labeled with a perfluorocarbon (PFC) nanoemulsion cell tracer...
June 2023: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/37258038/cell-surface-marker-based-capture-of-neoantigen-reactive-cd8-t-cell-receptors-from-metastatic-tumor-digests
#29
JOURNAL ARTICLE
Praveen D Chatani, Frank J Lowery, Neilesh B Parikh, Kyle J Hitscherich, Rami Yossef, Victoria Hill, Jared J Gartner, Biman Paria, Maria Florentin, Satyajit Ray, Alakesh Bera, Maria Parkhust, Paul Robbins, Sri Krishna, Steven A Rosenberg
BACKGROUND: Cellular immunotherapies using autologous tumor-infiltrating lymphocytes (TIL) can induce durable regression of epithelial cancers in selected patients with treatment-refractory metastatic disease. As the genetic engineering of T cells with tumor-reactive T-cell receptors (TCRs) comes to the forefront of clinical investigation, the rapid, scalable, and cost-effective detection of patient-specific neoantigen-reactive TIL remains a top priority. METHODS: We analyzed the single-cell transcriptomic states of 31 neoantigen-specific T-cell clonotypes to identify cell surface dysfunction markers that best identified the metastatic transcriptional states enriched with antitumor TIL...
May 2023: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/37226502/potential-inhibitory-effect-of-geraniol-isolated-from-lemongrass-cymbopogon-commutatus-stapf-on-tilmicosin-induced-oxidative-stress-in-cardiac-tissue
#30
JOURNAL ARTICLE
Rebai Ben Ammar, Sarah Abdulaziz Alamer, Maged Elsayed Mohamed, Duaa Althumairy, Saeed Y Al-Ramadan, Manal Alfwuaires, Nancy S Younis, Thnaian A Althnaian, Ibrahim R I H, Peramaiyan Rajendran
An experimental study has been conducted to investigate the efficacy of geraniol (GNL) isolated from lemomgrass in protecting against cardiac toxicity induced by tilmicosin (TIL) in albino mice. Compared to TIL-treated mice, those supplemented with GNL had a thicker left ventricular wall and a smaller ventricular cavity. Studies of TIL animals treated with GNL showed that their cardiomyocytes had markedly changed in diameter and volume, along with a reduction in numerical density. After TIL induction, animals showed a significant increase in the protein expression of TGF-β1, TNF-α, nuclear factor kappa B (NF-kB), by 81...
May 24, 2023: Natural Product Research
https://read.qxmd.com/read/37189103/epigenetic-reprogramming-of-runx3-reinforces-cd8%C3%A2-%C3%A2-t-cell-function-and-improves-the-clinical-response-to-immunotherapy
#31
JOURNAL ARTICLE
Zongzhi Liu, Xiang Li, Yibo Gao, Jiejie Liu, Yating Feng, Yang Liu, Junyun Wang, Chunmeng Wang, Dongrui Wang, Jie He, Weidong Han, Qian Mei, Yingli Sun
BACKGROUND: Checkpoint blockade immunotherapy, represented by PD-1 or PD-L1 antibody treatment, has been of tremendous success in clinical practice. However, the low clinical response rate and lack of biomarkers for prediction of the immune response limit the clinical application of anti-PD-1 immunotherapy. Our recent work showed that a combination of low-dose decitabine and PD-1-ab significantly improved the complete response (CR) rate of cHL patients from 32 to 71%, which indicates that there is a significant correlation between epigenetic regulation and the clinical response to immunotherapy...
May 16, 2023: Molecular Cancer
https://read.qxmd.com/read/37149505/pentoxifylline-changes-the-balance-of-immune-cell-population-in-breast-tumor-infiltrating-lymphocytes
#32
JOURNAL ARTICLE
Mohammad Hossein Kazemi, Mahdieh Shokrollahi Barough, Zahra Momeni-Varposhti, Alireza Ghanavatinejad, Ali Zarehzadeh Mehrabadi, Behnam Sadeghi, Reza Falak
Immunotherapy utilizing tumor-infiltrating lymphocytes (TILs) is a promising approach for cancer treatment. Pentoxifylline (PTXF), a xanthine derivative, exhibits antitumor properties. This study aimed to investigate the impact of PTXF on the phenotype and function of TILs and splenocytes in a triple-negative breast cancer (TNBC) mouse model. TNBC was subcutaneously induced in BALB/c mice, followed by nine intraperitoneal injections of 100 mg/kg PTXF. TILs were then isolated by enzymatic digestion of tumors and cocultured with 4T1 cells...
May 6, 2023: Medical Oncology
https://read.qxmd.com/read/37131688/predicting-neoadjuvant-treatment-response-in-triple-negative-breast-cancer-using-machine-learning
#33
Shristi Bhattarai, Geetanjali Saini, Hongxiao Li, Hongyi Duanmu, Gaurav Seth, Timothy B Fisher, Emiel A M Janssen, Umay Kiraz, Jun Kong, Ritu Aneja
BACKGROUND: Neoadjuvant chemotherapy (NAC) is the standard treatment for early-stage triple negative breast cancer (TNBC). The primary endpoint of NAC is a pathological complete response (pCR). NAC results in pCR in only 30%â€"40% of TNBC patients. Tumor-infiltrating lymphocytes (TILs), Ki67 and phosphohistone H3 (pH3) are a few known biomarkers to predict NAC response. Currently, systematic evaluation of the combined value of these biomarkers in predicting NAC response is lacking...
April 20, 2023: bioRxiv
https://read.qxmd.com/read/37087548/-establishment-of-culture-system-for-selective-amplification-of-cd8-t-cells-in-vitro-and-analysis-of-its-functional-and-molecular-phenotypes-from-tumor-infiltrating-lymphocytes-in-malignant-pleural-ascites
#34
JOURNAL ARTICLE
Jiameng Liu, Chaoming Mao, Fei Ye, Xiao Yuan
Objective To explore the culture method of mass amplification for tumor-infiltrating lymphocytes (TILs) from malignant pleural/ascites in vitro, and identify the function and molecular phenotype of these amplified cells. Methods The pleural/ascites fluid was extracted under aseptic conditions, and lymphocytes were isolated by density gradient centrifugation. Then TILs were amplified by the program based on combined IFN-γ, OKT3 and IL-2, and the cell morphology and growth rate were recorded. The molecular phenotypes of the amplified lymphocytes were analyzed by Flow cytometry, and the killing ability against tumor cells was detected by CCK-8 assay...
April 2023: Xi Bao Yu Fen Zi Mian Yi Xue za Zhi, Chinese Journal of Cellular and Molecular Immunology
https://read.qxmd.com/read/37045473/specific-recognition-of-an-fgfr2-fusion-by-tumor-infiltrating-lymphocytes-from-a-patient-with-metastatic-cholangiocarcinoma
#35
JOURNAL ARTICLE
Bradley Sinclair White, Sivasish Sindiri, Victoria Hill, Billel Gasmi, Shirley Nah, Jared J Gartner, Todd D Prickett, Yong Li, Devikala Gurusamy, Paul Robbins, Steven A Rosenberg, Vid Leko
BACKGROUND: Metastatic cholangiocarcinoma (CC), a form of gastrointestinal cancer that originates from the bile ducts, cannot be cured by currently available therapies, and is associated with dismal prognosis. In a previous case report, adoptive transfer of autologous tumor infiltrating lymphocytes (TILs), the majority of which recognized a tumor-specific point mutation, led to a profound and durable cancer regression in a patient with metastatic CC. Thus, more effective treatment for patients with this disease may be developed by using TILs that target cancer-specific mutations, but also other genetic aberrations such as gene fusions...
April 2023: Journal for Immunotherapy of Cancer
https://read.qxmd.com/read/36988342/single-cell-analysis-of-localized-prostate-cancer-patients-links-high-gleason-score-with-an-immunosuppressive-profile
#36
JOURNAL ARTICLE
Victor R Adorno Febles, Yuan Hao, Aarif Ahsan, Jiansheng Wu, Yingzhi Qian, Hua Zhong, Stacy Loeb, Danil V Makarov, Herbert Lepor, James Wysock, Samir S Taneja, William C Huang, Daniel J Becker, Arjun V Balar, Jonathan Melamed, Fang-Ming Deng, Qinghu Ren, Donald Kufe, Kwok-Kin Wong, Dennis O Adeegbe, Jiehui Deng, David R Wise
BACKGROUND: Evading immune surveillance is a hallmark for the development of multiple cancer types. Whether immune evasion contributes to the pathogenesis of high-grade prostate cancer (HGPCa) remains an area of active inquiry. METHODS: Through single-cell RNA sequencing and multicolor flow cytometry of freshly isolated prostatectomy specimens and matched peripheral blood, we aimed to characterize the tumor immune microenvironment (TME) of localized prostate cancer (PCa), including HGPCa and low-grade prostate cancer (LGPCa)...
March 29, 2023: Prostate
https://read.qxmd.com/read/36893559/combined-phospholipids-adjuvant-augments-anti-tumor-immune-responses-through-activated-tumor-associated-dendritic-cells
#37
JOURNAL ARTICLE
Yifang Shui, Xin Hu, Hiroshi Hirano, Hirotake Tsukamoto, Wen-Zhi Guo, Kenichiro Hasumi, Fumihiro Ijima, Masayuki Fujino, Xiao-Kang Li
Dendritic cells (DCs) can initiate both naïve and memory T cell activation, as the most potent antigen-presenting cells. For efficient anti-tumor immunity, it is essential to enhance the anti-tumoral activity of tumor-associated DCs (TADCs) or to potently restrain TADCs so that they remain immuno-stimulating cells. Combined phospholipids (cPLs) adjuvant may act through the activation of DCs. This study demonstrated the potential mechanism of tumor growth inhibition of cPLs adjuvant, and confirmed that cPLs adjuvant could induce the maturation and activation (upregulation of MHC-II, CD80, CD40, IL-1β, IL-12, IL-6 expression) of BMDCs in vitro...
March 7, 2023: Neoplasia: An International Journal for Oncology Research
https://read.qxmd.com/read/36775787/generation-of-colon-cancer-derived-tumor-infiltrating-t-cells-tils-for-adoptive-cell-therapy
#38
JOURNAL ARTICLE
Hendrik Christian Albrecht, Dirk Gustavus, Jannis Schwanemann, Werner Dammermann, Frank Lippek, Karsten-Henrich Weylandt, Hans Hoffmeister, Stephan Gretschel
Adoptive cell therapy (ACT) using specific immune cells and stem cells has emerged as a promising treatment option that could complement traditional cancer therapies in the future. In particular, tumor-infiltrating lymphocytes (TILs) have been shown to be effective against solid tumors in various clinical trials. Despite the enormous disease burden and large number of premature deaths caused by colorectal cancer (CRC), studies on TILs isolated from tumor tissue of patients with CRC are still rare. To date, studies on ACT often lack controlled and comparable expansion processes as well as selected ACT-relevant T-cell populations...
February 10, 2023: Cytotherapy
https://read.qxmd.com/read/36730099/mechanisms-of-hamstring-injury-in-professional-soccer-players-video-analysis-and-magnetic-resonance-imaging-findings
#39
JOURNAL ARTICLE
Aleksi Jokela, Xavier Valle, Jussi Kosola, Gil Rodas, Lluís Til, Maria Burova, Pavel Pleshkov, Håkan Andersson, Giulio Pasta, Paolo Manetti, Gabriel Lupón, Ricard Pruna, Alvaro García-Romero-Pérez, Lasse Lempainen
OBJECTIVE: To describe the injury mechanisms and magnetic resonance imaging (MRI) findings in acute hamstring injuries of male soccer players using a systematic video analysis. DESIGN: Descriptive case series study of consecutive acute hamstring injuries from September 2017 to January 2022. SETTING: Two specialized sports medicine hospitals. PARTICIPANTS: Professional male soccer players aged between 18 and 40 years, referred for injury assessment within 7 days after an acute hamstring injury, with an available video footage of the injury and positive finding on MRI...
May 1, 2023: Clinical Journal of Sport Medicine
https://read.qxmd.com/read/36717657/cd8-cd226-high-t-cells-in-liver-metastases-dictate-the-prognosis-of-colorectal-cancer-patients-treated-with-chemotherapy-and-radical-surgery
#40
JOURNAL ARTICLE
Julien Viot, Syrine Abdeljaoued, Angélique Vienot, Evan Seffar, Laurie Spehner, Adeline Bouard, Kamal Asgarov, Jean-René Pallandre, Elodie Renaude, Elodie Klajer, Chloé Molimard, Franck Monnien, Frederic Bibeau, Celia Turco, Bruno Heyd, Paul Peixoto, Eric Hervouet, Romain Loyon, Alexandre Doussot, Christophe Borg, Marie Kroemer
CD226 has been reported to participate in the rescue of CD8+ T cell dysfunction. In this study, we aimed to assess the prognostic value of CD226 in tumor-infiltrating lymphocytes (TILs) derived from colorectal cancer (CRC) liver metastases treated with chemotherapy and radical surgery. TILs from 43 metastases were isolated and analyzed ex vivo using flow cytometry. CD155 and CD3 levels in the tumor microenvironment were assessed by immunohistochemistry. Exploration and validation of biological processes highlighted in this study were performed by bioinformatics analysis of bulk RNA-seq results for 28 CRC liver metastases pretreated with chemotherapy as well as public gene expression datasets...
January 30, 2023: Cellular & Molecular Immunology
keyword
keyword
104654
2
3
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.